Novartis AG Chief Executive Officer Vas Narasimhan said proposed US restrictions on biotech investments in China could hamper the development of new medicines, according to Bloomberg.
Novartis AG Chief Executive Officer Vas Narasimhan said proposed US restrictions on biotech investments in China could hamper the development of new medicines, according to Bloomberg.